Markets:

Overview

News

Currencies

International

Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

4.570 UNCHANGED

Streaming Delayed Price Updated: 4:15 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Altimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

MarketBeat Week in Review – 11/4 - 11/8

November 09, 2024

Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts

Via MarketBeat

Topics Economy Government

How Altimmune Could Grab a Big Chunk of the GLP-1 Market

November 08, 2024

Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users.

Via MarketBeat

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names ↗

October 11, 2024

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Via Benzinga

1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc) ↗

September 17, 2024

Telemedicine once seemed like it was going to revolutionize healthcare.

Via The Motley Fool

Decoding 4 Analyst Evaluations For Altimmune ↗

August 22, 2024

Via Benzinga

ALT Stock Earnings: Altimmune Misses EPS for Q2 2024 ↗

August 08, 2024

ALT stock results show that Altimmune missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

3 Promising Biotech Stocks for the Long-Term: August 2024 ↗

August 13, 2024

Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.

Via InvestorPlace

The 7 Best Under $10 Stocks to Buy in August 2024 ↗

August 11, 2024

Buying low-priced stocks carries risk, but lower interest rates may lower the risk premium on these best stocks under $10.

Via InvestorPlace

Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year ↗

August 09, 2024

Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.

Via The Motley Fool

Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now. ↗

August 02, 2024

Via The Motley Fool

Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? ↗

July 20, 2024

At least one of the pair has a credible shot at finding a home in the market.

Via The Motley Fool

Forecasting The Future: 5 Analyst Projections For Altimmune ↗

June 21, 2024

Via Benzinga

How Is The Market Feeling About Altimmune? ↗

June 03, 2024

Via Benzinga

3 Undervalued Biotech Stocks With Breakout Potential ↗

July 19, 2024

Invest in these three undervalued biotech stocks with double-digit upside ahead driven by cutting-edge healthcare advancements

Via InvestorPlace

Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio ↗

July 17, 2024

These three wild-card stocks will spice up your portfolio in ways boring diversification never could, so read on.

Via InvestorPlace

Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics ↗

July 10, 2024

Both competitors have promising lead programs, and enough cash, too.

Via The Motley Fool

7 Bullish Stock Picks With the Potential to Turn $5K Into $50K ↗

July 09, 2024

These high-potential stock picks each have 10X potential moving forward and are well worth understanding despite high prices in some cases.

Via InvestorPlace

The 7 Best Under $10 Stocks to Buy in July 2024 ↗

July 06, 2024

We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now.

Via InvestorPlace

3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics ↗

June 30, 2024

While their share prices have traveled different paths recently, the similarity between the two companies is striking.

Via The Motley Fool

If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy ↗

June 29, 2024

The market for weight loss medicines keeps getting hotter and hotter.

Via The Motley Fool

The 3 Smartest Biotech Stocks to Buy With $5K Right Now ↗

June 28, 2024

With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs.

Via InvestorPlace

Why Are Altimmune Shares Trading Lower Wednesday? ↗

June 26, 2024

Altimmune shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the company's Chief Financial Officer.

Via Benzinga

Why Is Alimera Sciences (ALIM) Stock Up 77% Today? ↗

June 24, 2024

Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals.

Via InvestorPlace

BITF Stock Alert: Riot Platforms Is Changing Its Approach to Take Over Bitfarms ↗

June 24, 2024

Bitfarms stock is down on Monday after Riot Platforms withdrew its offer for BITF stock in favor of nominating new board memebers.

Via InvestorPlace

ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings ↗

June 24, 2024

Altimmune (ALT) stock is soaring and trending after the company reported data on its GLP-1 weight-loss drug today.

Via InvestorPlace

Altimmune Stock Is Rising Monday: What's Driving The Action? ↗

June 24, 2024

Altimmune said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a recently completed body composition analysis at the American Diabetes...

Via Benzinga

RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 24, 2024

Via Benzinga

3 Stocks Under $10 Set to Quadruple by 2025: June Edition ↗

June 13, 2024

Low-priced stocks under $10 can be explosively awarding if you spot the right one at the right time with the right catalyst.

Via InvestorPlace

3 Stocks Quietly Preparing for a 10X Surge: June Edition ↗

June 12, 2024

There are plenty of 10x stocks with the potential to surge 10x over. We’ve already seen in happen with Apple, Netflix, Microsoft and Nvidia.

Via InvestorPlace

The 3 Most Undervalued Biotech Stocks to Buy in June 2024 ↗

June 04, 2024

https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Altimmune, Inc. - Common Stock (NQ:ALT)

Headline News about Altimmune, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today